EMA annual report reviews actions in 2022
The European Medicines Agency (EMA) has published its annual report for 2022, highlighting its challenges and successes in a year that saw it face ongoing and new public health emergencies.
#marketaccess
Tag
Will ABPI’s ambitious VPAG plans succeed VPAS?
Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.
EC’s plans for updating pharma legislation unveiled
The European Commission’s (EC) long-awaited proposals for reforming pharma legislation have been published. The main thrust of the proposals is to create a single EU market for medicines to replace existing fragmentation and improve access for EU citizens.
NICE extends international collaboration to streamline processes
The UK’s National Institute for health and Care Excellence (NICE) has announced that it will be working closely with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the US Institute for Clinical and Economic Review (ICER) to find common ground and smooth processes around the handling of confidential information about health technologies.
BIA calls on NICE to update evidence on rare disease medicines
New research has found that the public believes a new approach should be adopted for making funding decisions about treatments for rare diseases. The report ‘Rare insights: examining the social values of treating rare diseases’, was commissioned by the UK BioIndustry Association’s (BIA) Rare Disease Industry Group (RDIG).
EFPIA Director General calls for action on pharma legislation
The head of the European Federation of Pharmaceutical Industries and Associations (EFPIA), Nathalie Moll, has outlined two urgent actions that European pharma needs as the announcement of the EU’s pharma strategy has been postponed again by the European Commission.
OHE Innovation Policy Prize
The Office of Health Economics (OHE) launched a biennial competition in early 2022 to answer the question ‘How can policymakers design a system to generate fair prices that balances access and innovation throughout the lifecycle of medicines?’ Join the live online ceremony on 24 January 2023.
ABPI asks UK government to review VPAS as clawback will hit 26.5% of sales revenue in 2023
In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).
ATMPs for rare diseases a priority for Innovative Health Initiative funding
Research themes under consideration for the next round of Innovative Health Initiative (IHI) funding include Topic 4: Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases.